Changchun GeneScience Pharmaceutical
CompanyChina
Changchun GeneScience Pharmaceutical develops one asset, approved (CAMCEVI in advanced prostate cancer). Mostly peptide acting on GNRHR; based in China.
- 1
- Asset
- Furthest stage
- Approved
- 8
- Trials
- 1
- Signal
Pipeline
1Sustained GnRH receptor agonism suppresses gonadotropin release and testosterone production.
Approved, Peptide, GNRHR, advanced prostate cancer, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials8
- Signals1
- Similar companies1